View in EDS HTML Full Text PDF Full Text

Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.

Saved in:
Bibliographic Details
Title: Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
Authors: Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Looze EJ; Division of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Thavaneswaran S; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., van Berge Henegouwen JM; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Simes RJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Sjoquist KM; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., van der Wijngaart H; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands., Sebastian L; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Lee CK; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., de Wit GF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Espinoza D; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands., Lin FP; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Jansen AML; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., de Leng WWJ; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., van der Noort V; Biometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Leek LVM; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Vos FYFL; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Thomas DM; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia., Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.
Source: International journal of cancer [Int J Cancer] 2023 Oct 01; Vol. 153 (7), pp. 1413-1422. Date of Electronic Publication: 2023 Jul 10.
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37424386
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zeverijn+LJ%22">Zeverijn LJ</searchLink>; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Looze+EJ%22">Looze EJ</searchLink>; Division of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Thavaneswaran+S%22">Thavaneswaran S</searchLink>; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22van+Berge+Henegouwen+JM%22">van Berge Henegouwen JM</searchLink>; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Simes+RJ%22">Simes RJ</searchLink>; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22Hoes+LR%22">Hoes LR</searchLink>; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Sjoquist+KM%22">Sjoquist KM</searchLink>; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22van+der+Wijngaart+H%22">van der Wijngaart H</searchLink>; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Sebastian+L%22">Sebastian L</searchLink>; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22Geurts+BS%22">Geurts BS</searchLink>; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Lee+CK%22">Lee CK</searchLink>; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22de+Wit+GF%22">de Wit GF</searchLink>; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Espinoza+D%22">Espinoza D</searchLink>; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22Roepman+P%22">Roepman P</searchLink>; Hartwig Medical Foundation, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Lin+FP%22">Lin FP</searchLink>; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22Jansen+AML%22">Jansen AML</searchLink>; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Leng+WWJ%22">de Leng WWJ</searchLink>; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Noort+V%22">van der Noort V</searchLink>; Biometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Leek+LVM%22">Leek LVM</searchLink>; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Vos+FYFL%22">de Vos FYFL</searchLink>; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Herpen+CML%22">van Herpen CML</searchLink>; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Gelderblom+H%22">Gelderblom H</searchLink>; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Verheul+HMW%22">Verheul HMW</searchLink>; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Thomas+DM%22">Thomas DM</searchLink>; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22Voest+EE%22">Voest EE</searchLink>; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220042124%22">International journal of cancer</searchLink> [Int J Cancer] 2023 Oct 01; Vol. 153 (7), pp. 1413-1422. <i>Date of Electronic Publication: </i>2023 Jul 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Liss%22">Wiley-Liss </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0042124 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0215 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200207136%22">00207136 </searchLink><i>NLM ISO Abbreviation: </i>Int J Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37424386
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/ijc.34649
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1413
    Titles:
      – TitleFull: Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zeverijn LJ
      – PersonEntity:
          Name:
            NameFull: Looze EJ
      – PersonEntity:
          Name:
            NameFull: Thavaneswaran S
      – PersonEntity:
          Name:
            NameFull: van Berge Henegouwen JM
      – PersonEntity:
          Name:
            NameFull: Simes RJ
      – PersonEntity:
          Name:
            NameFull: Hoes LR
      – PersonEntity:
          Name:
            NameFull: Sjoquist KM
      – PersonEntity:
          Name:
            NameFull: van der Wijngaart H
      – PersonEntity:
          Name:
            NameFull: Sebastian L
      – PersonEntity:
          Name:
            NameFull: Geurts BS
      – PersonEntity:
          Name:
            NameFull: Lee CK
      – PersonEntity:
          Name:
            NameFull: de Wit GF
      – PersonEntity:
          Name:
            NameFull: Espinoza D
      – PersonEntity:
          Name:
            NameFull: Roepman P
      – PersonEntity:
          Name:
            NameFull: Lin FP
      – PersonEntity:
          Name:
            NameFull: Jansen AML
      – PersonEntity:
          Name:
            NameFull: de Leng WWJ
      – PersonEntity:
          Name:
            NameFull: van der Noort V
      – PersonEntity:
          Name:
            NameFull: Leek LVM
      – PersonEntity:
          Name:
            NameFull: de Vos FYFL
      – PersonEntity:
          Name:
            NameFull: van Herpen CML
      – PersonEntity:
          Name:
            NameFull: Gelderblom H
      – PersonEntity:
          Name:
            NameFull: Verheul HMW
      – PersonEntity:
          Name:
            NameFull: Thomas DM
      – PersonEntity:
          Name:
            NameFull: Voest EE
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2023 Oct 01
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1097-0215
          Numbering:
            – Type: volume
              Value: 153
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: International journal of cancer
              Type: main
ResultId 1